# OnCo record locally-advanced-bcc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/locally-advanced-bcc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "locally-advanced-bcc" ;
  schema:name "Locally advanced and metastatic basal cell carcinoma"@en ;
  schema:alternateName "Advanced basal cell carcinoma"@en, "Unresectable basal cell carcinoma"@en, "Metastatic basal cell carcinoma"@en, "Hedgehog inhibitor-treated basal cell carcinoma"@en ;
  schema:description "Locally advanced basal cell carcinoma is a skin cancer that has grown so large or deep, usually on the face, that surgery or radiotherapy can no longer remove it without unacceptable damage. Almost all these tumours depend on the hedgehog growth pathway, and the pills vismodegib and sonidegib shrink about four in ten of them; cemiplimab is used when the pills fail or cannot be tolerated."@en ;
  schema:url <https://onco.cc/cancers/locally-advanced-bcc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Basal-cell_carcinoma> ;
  schema:citation <https://www.nejm.org/doi/full/10.1056/NEJMoa1113713>, <https://doi.org/10.1016/S1470-2045(21)00126-1>, <https://en.wikipedia.org/wiki/Basal-cell_carcinoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/basal-cell-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/hedgehog-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/technologies/superficial-radiotherapy/>, <https://onco.cc/technologies/electron-beam-therapy-systems/> ;
  onco:targets <https://onco.cc/targets/smoothened/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/drugs/cemiplimab/> ;
  onco:pathways <https://onco.cc/pathways/hedgehog/>, <https://onco.cc/pathways/basal-cell-carcinoma-signalling/> ;
  onco:trials <https://onco.cc/trials/erivance/>, <https://onco.cc/trials/bolt/> ;
  onco:pipeline <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/trials/nct06344052/>, <https://onco.cc/trials/nct06422936/>, <https://onco.cc/trials/nct06050122/>, <https://onco.cc/trials/nct04349436/>, <https://onco.cc/technologies/hedgehog-inhibitors/> ;
  onco:standardOfCare <https://onco.cc/trials/erivance/>, <https://onco.cc/trials/bolt/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/technologies/hedgehog-inhibitors/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/trials/nct06422936/>, <https://onco.cc/trials/nct04349436/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/superficial-radiotherapy/>, <https://onco.cc/technologies/electron-beam-therapy-systems/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/trials/nct06050122/> .